

YARARLANILAN VE ÖNERİLEN KAYNAKLAR

- Buharaloğlu, C.K. Farmakovijilans: Eczacıların Genişleyen Sorumluluk Alanı, *Güncel Eczacılık*, 129: 15-18, 2004.
- Buharaloğlu, C.K. Farnasötillerin global harmonizasyonu: ICH girişimi ve inovatör firmaların yaklaşımı. *TÜFTAD Haberler*, 9(3): 13-16, 2002.
- Buharaloğlu, C.K. İlaçla tedavi problemlerinde klinik eczacılık hizmetleri nasıl katkıda bulunabilir?, *Güncel Eczacılık*, 131: 15-17, 2004.
- Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., Schaff, H.V. Valvular heart disease associated with fenfluramine - phentermine. *N Engl J Med*. 337(9): 581-8, 1997.
- Cripps, D.J., Gocmen, A. Peters, H.A. Porphyria turcica. Twenty years after hexachlorobenzene intoxication. *Arch Dermatol*. 116(1):46-50, 1980.
- Davies DM. History and epidemiology. *Textbook Of Adverse Drug Reactions'de* (Ed.: Davics DM.) 3rd ed. New York: Oxford University Press;12-38, 1986.
- Dillner, L. Pill scare linked to rise in abortions. *BMJ*. 312(7037): 996, 1996.
- Evans, S.J., Pharmacovigilance: a science or fielding emergencies?, *Statist In Medicine* 19: 3199-3209, 2000.
- Fung, M., Thornton, A., Mybeck, K., Hsiao-Hui Wu, J., Hornbuckle, K., Muniz, E. Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs From Worldwide Pharmaceutical Markets—1960 to 1999. *Drug Information Journal*, 35:293–317, 2001.
- Hepler, C.D., Strand, L.M.. Opportunities and responsibilities in pharmaceutical care. *Am J Hosp Pharm*, 47: 533, 1990.
- Kara, İ.H., Güloğlu, C., Karabulut, A., Orak, M., Sociodemographic, Clinical, and Laboratory Features of Cases of Organic Phosphorus Intoxication Who Attended the Emergency Department in the Southeast Anatolian Region of Turkey. *Environmental Research*, 88: 2, 82-88, 2002.
- Laidler, P., Maslin, S.C., Gilhorne, R.W. What's new in Osmosin and intestinal perforation? *Pathol Res Pract*. 180(1): 74-6, 1985.
- Lasser, K.E., Allen, P.D., Woolhandler, S.J., Himmelstein, D.U., Wolfe, S.M., Bor, D.H. Timing of new black box warnings and withdrawals for prescription medications. *JAMA* 287(17):2215-20, 2002.
- Lazarotti, J., Pomeranz, B.H., Corey, P.N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 279(15): 1200-5, 1998.
- Lexchin, J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. *CMAJ* 172(6): 765-7, 2005.

- Nies, A.S. Principles of Therapeutics. Goodman and Gilman's the Pharmacological Basis of Therapeutics'de (Ed.: Hardman, J.G.ve diğ.), s. 45-67, 10. Baskı, McGraw-Hill Professional, 2001.
- Oğuz Kayaalp, Klinik Farmakolojinin Esasları ve Temel Düzenlemeler, Farmakovijilans, s. 238-257, 2. Baskı, Hacettepe-Taş Kitapçılık Ltd.Şti., 2002.
- Phillips, K.A., Veenstra, D.L., Oren, E., Lee, J.K., Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 14;286(18):2270-9, 2001.
- Sağlık Bakanlığı: Beşeri Tıbbi Ürünlerin Güvenliğinin İzlenmesi ve Değerlendirilmesi Hakkında Yönetmelik. Resmi Gazete Sayı: 25763, 22.3.2005, Ankara.
- Sağlık Bakanlığı: Beşeri Tıbbi Ürün Ruhsatı Sahipleri İçin Farmakovijilans Kılavuzu. 30.6.2005'de yürürlüğe girmiştir.
- Sağlık Bakanlığı: Farmasötik ve Tıbbi Müstahzar, Madde, Malzeme, Terkipler ile Bitkisel Preparatların Geri Çekilmesi ve Toplanması Hakkında Yönetmelik. Resmi Gazete Sayı: 19196, 15.08.1986, Ankara.
- Safety of Medicines: A guide to detecting and reporting adverse drug reactions, World Health Organization, Geneva 2002.
- Svensson, C.K., Cowen, E.W., Gaspari, A.A. Cutaneous Drug Reactions, Pharmacol Rev 53:357-379, 2000.
- Stergachis, A.: Pharmacoepidemiology. Pharmacotherapy: A Pathophysiologic Approach'de (Ed.: Dipiro ve diğ.), McGraw-Hill, New York, 2001.
- Şule Oktay ve Oğuz Kayaalp: Reçete Yazma Kuralları ve Rasyonel İlaç Kullanımı. Rasyonel Tedavi Yönlünden Tıbbi Farmakoloji'de (Ed.: Oğuz Kayaalp), 167-181, 10. Baskı, Hacettepe-Taş Kitapçılık Ltd.Şti., 2002.
- Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology. 20 Suppl:S20-4, 2000.
- The Centres for Education and research on Therapeutics (CERTs) Risk Assessment Workshop Participants, Risk assessment of drugs, biologics and therapeutic devices: present and future issues, Pharmacoepidemiol Drug Safety, 12, 653-662, 2003.
- The importance of pharmacovigilance, Safety monitoring of medicinal products, World Health Organization, WHO Collaborating Centre for International Drug Monitoring, 2002
- Tunger, O, Dinc, G, Ozbakkaloglu, B, Atman, U.C., Algun. U. Evaluation of rational antibiotic use. Int J Antimicrob Agents. 15(2): 131-5, 2000.
- Türkiye İlaç Kılavuzu 2005 Formülleri, Editör Oğuz Kayaalp, Targut Yayıncılık ve Ticaret A.Ş., 2005.
- Vallano, A., Cereza, G., Pedròs C., Agustí, A., Danés, I., Aguilera, C., Arnau, J. M. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital Br J Clin Pharmacol 60(6): 653-658, 2005.
- van Grootheest, K., Olsson, S., Couper, M., de Jong-van den Berg, L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 13(7): 457-64, 2004.
- van Grootheest, A.C., van Puijenbroek, E.P., de Jong-van den Berg, L.T. Contribution of pharmacists to the reporting of adverse drug reactions Pharmacoepidemiol Drug Saf. 11(3):205-10, 2002.

Waller, P.C., Lee, E.H., Responding drug safety issues, *Pharmacoepidemiol Drug Safety*, 8, 535-552, 1999.

Waller, P.C., Stephen, J., Evans, W. A model for the future conduct of pharmacovigilance. *Pharmacoepidemiology and Drug Safety* 12: 17-29, 2003.

Wysowski, D.K., Gren, L., Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. *Obstet Gynecol* 85(4): 538-42, 1995.